Prioritizing Medical Countermeasures for National Security Act of 2023

This bill creates a new federal list of drugs needed to address national security threats like chemical, biological, radiological, or nuclear attacks. It requires the Health and Human Services Secretary to maintain this list, considering factors like public health needs and input from the Defense Department, and to periodically update it based on current threats. Drug developers seeking faster FDA review for these countermeasures must align with the list, which will be publicly accessible. The program's deadline for review is extended from 2023 to 2029, and a report on its effectiveness will be required by 2027. The bill directly affects pharmaceutical companies developing medical countermeasures and federal agencies managing national health security.